THE Therapeutic Goods Administration (TGA) has confirmed a second case of thrombosis with thrombocytopenia syndrome (TTS) in a patient who received the AstraZeneca (AZ) COVID-19 vaccine (COVAX).
The TGA's Vaccine Safety Investigation Group (VSIG) revealed the case was "likely to be linked to vaccination", with the patient - a women in her 40s who received the shot in Western Australia - currently in a stable condition in hospital.
"There have been about 700,000 doses of AZ COVAX administered in Australia to date, so while numbers are small, two cases of the TTS equates to a frequency of one in 350,000," the TGA said.
CLICK HERE for more.
The above article was sent to subscribers in Pharmacy Daily's issue from 13 Apr 21
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 13 Apr 21